SCHEMBL6080405

SCHEMBL6080405

COC(=O)c1cc(N)c2cccc(O)c2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 3/20 0.47
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
PKM P14618 1/20 0.43
CYP1A2 P05177 2/20 0.42
PARP1 P09874 2/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
LCK P06239 1/20 0.42
LMNA P02545 2/20 0.41
PTGER4 P35408 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6079787 0.88 NQO2 (0.49) NQO2KDM4EALDH1A1MAPTPKM
SCHEMBL6080401 0.83 NQO2 (0.47) NQO2CA12CA1CA2CA7
SCHEMBL6079537 0.82 KDM4E (0.54) KDM4ECYP1A2PARP1CYP2D6CYP2C9
SCHEMBL1315731 0.78 KDM4E (0.52) NQO2KDM4EALDH1A1MAPTPKM
SCHEMBL6079612 0.77 CYP4A11 (0.40) CA12CA1CA2CA7CA9
SCHEMBL6080554 0.77 CYP4A11 (0.40) CA12CA1CA2CA7CA9
SCHEMBL6079496 0.76 KDM4E (0.43) CA12CA1CA2CA7CA9
SCHEMBL6080007 0.76 KDM4E (0.45) KDM4EALDH1A1MAPTCYP1A2CYP2C9
SCHEMBL1401134 0.75 MAPT (0.45) CA12CA1CA2CA7CA9
SCHEMBL6080286 0.75 NQO2 (0.45) NQO2KDM4EALDH1A1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL NQO2 2/4885CA12 3292/4885CA1 2702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.